NCT00652483已完成3 期
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Allergan
- 入组人数
- 433
- 主要终点
- Intraocular pressure (IOP)
研究概览
简要总结
This study evaluates the safety and efficacy of brimonidine 0.1% ophthalmic solution compared with brimonidine 0.2% ophthalmic solution in patients with glaucoma or ocular hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ocular hypertension or glaucoma in both eyes
排除标准
- •Uncontrolled systemic disease
- •Known allergy or sensitivity to brimonidine
研究组 & 干预措施
1
Experimental
Brimonidine ophthalmic solution 0.1%
干预措施: Brimonidine ophthalmic solution 0.1% (Drug)
2
Active Comparator
Brimonidine ophthalmic solution 0.2%
干预措施: Brimonidine ophthalmic solution 0.2% (Drug)
结局指标
主要结局
Intraocular pressure (IOP)
时间窗: Week 2 - Month 3
次要结局
- IOP(Month 6 - Month 12)
研究者
相似试验
已完成
3 期
Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00168363Allergan207
终止
2 期
A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular DegenerationGeographic AtrophyMacular DegenerationNCT02087085Allergan310
已完成
3 期
Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00652106Allergan432
已完成
2 期
Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric SubjectsOcular RednessNCT01675609Eye Therapies, LLC57
已完成
3 期
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular HypertensionOpen-Angle GlaucomaOcular HypertensionNCT00061529Alcon Research